ArticleCell proliferation2017
Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer.
Article in Cell proliferation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Deubiquitination of Vangl by USP6 and USP32 Regulates Planar Cell Polarity Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesisTheranostics · 2026Article
- USP32 promotes temporomandibular joint osteoarthritis by modulating PKM2 stability and glycolytic metabolism in chondrocytes.Cell death & disease · 2025Article
- USP32 Promotes Colorectal Carcinoma Progression Through Activating NF-κB Signalling Pathway.Journal of cellular and molecular medicine · 2025Article
- USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway.Oncogenesis · 2024Article
- High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma.BMC cancer · 2023Article
- USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target.Cell death discovery · 2023Review
- Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors.Journal of translational medicine · 2023Article
- Understanding The Regulatory Role of USP32 and SHMT2 in The Progression of Gastric Cancer.Cell journal · 2023Article
- Roles of the hsa_circ_0013880/USP32/Rap1b axis in the proliferation and apoptosis of acute myeloid leukemia cells.Acta biochimica et biophysica Sinica · 2023Article
- Identification of ubiquitin-specific protease 32 as an oncogene in glioblastoma and the underlying mechanisms.Scientific reports · 2022Article
- The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer.Frontiers in oncology · 2022Article
- Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.Acta pharmacologica Sinica · 2021Review
- USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.Theranostics · 2021Article
- USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2.International journal of biological sciences · 2020Article
- MicroRNA let-7a inhibits proliferation of breast cancer cell by downregulating USP32 expression.Translational cancer research · 2019Article
- USP32 regulates late endosomal transport and recycling through deubiquitylation of Rab7.Nature communications · 2019Article
- Review
- Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer.Cell proliferation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUbiquitin specific protease 32 (USP32) is a highly conserved but uncharacterized gene, which has been reported to be associated with growth of breast cancer cells. However, the role of USP32 in human small cell lung cancer (SCLC) has not been uncovered. The aim of this study was to investigate and evaluate the clinical significance of USP32 in patients with SCLC. MATERIALS AND
methodsExpression of USP32 was firstly investigated using public online data sets and then determined in SCLC tissues and cell lines using quantitative real-time PCR, Western blotting and immunohistochemical staining. SCLC cells were transfected with a small-interfering RNA targeting USP32 mRNA and analysed for cell viability, proliferation ability, cell cycle distribution, apoptosis and invasion.
resultsUSP32 was found to be overexpressed in SCLC tissues compared with normal tissues. High USP32 expression was significantly correlated with disease stage and invasion. In vitro experiments demonstrated that silencing of USP32 caused a significant decrease in the proliferation and migration rate of cells. Furthermore, USP32 silencing arrested cell cycle progression at G0/G1 phase via decreasing CDK4/Cyclin D1 complex and elevating p21. In addition, downregulation of USP32 significantly induced cell apoptosis by activating cleaved caspase-3 and cleaved PARP, as well as inhibiting cell invasiveness via altering epithelial mesenchymal transition expression.
conclusionsOur results suggest for the first time that USP32 is important for SCLC progression and might be a potential target for molecular therapy of SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.